Characteristics of chronic GVHD after cord blood transplantation

Bone Marrow Transplantation

Volumn 48, Issue 10, 2013, Pages 1285-1290

  Newell, L F ^a,b,c   Flowers, M E D ^a,b   Gooley, T A ^a,b   Milano, F ^a   Carpenter, P A ^a,b   Martin, P J ^a,b   Delaney, C ^a,b  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

chronic GVHD; cord blood transplantation; GVHD

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANASARCA; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CORD BLOOD STEM CELL TRANSPLANTATION; CORTICOSTEROID THERAPY; DISEASE COURSE; ENDOSCOPIC BIOPSY; FEMALE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFANT; LATE ACUTE GRAFT VERSUS HOST DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PERSISTENT ACUTE GRAFT VERSUS HOST DISEASE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT ACUTE GRAFT VERSUS HOST DISEASE; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SYSTEMIC THERAPY; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION IMMUNOLOGY; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84885598707     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2013.48     Document Type: Article

References (35)

1. Barker JN, Weisdorf DJ, Defor TE, Blazar BR, McGlave PB, Miller JS et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005; 105: 1343-1347. (Pubitemid 40170912)
2. MacMillan ML, Weisdorf DJ, Brunstein CG, Cao Q, Defor TE, Verneris MR et al. Acute graft-versus-host disease after unrelated donor umbilical cord blood transplantation: analysis of risk factors. Blood 2009; 113: 2410-2415.
3. Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004; 351: 2265-2275. (Pubitemid 39552742)
4. Brunstein CG, Laughlin MJ. Extending cord blood transplant to adults: dealing with problems and results overall (review). Semin Hematol 2010; 47: 86-96.
5. Brunstein CG, Gutman JA, Weisdorf DJ, Woolfrey AE, Defor TE, Gooley TA et al. Allogeneic hematopoietic cell transplantation for hematological malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010; 116: 4693-4699.
6. Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versusleukemia effect in recipients of 2 units. Blood 2009; 114: 4293-4299.
7. Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M et al. Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 2007; 109: 1322-1330. (Pubitemid 46220686)
8. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W et al. Effect of graft source on unrelated donor haemopoietic stem-cell tranpslantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 2010; 11: 653-660.
9. Narimatsu H, Miyakoshi S, Yamaguchi T, Kami M, Matsumura T, Yuji K et al. Chronic graft-versus-host disease following umbilical cord blood transplantation: retrospective survey involving 1072 patients in Japan. Blood 2008; 112: 2579-2582.
10. Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant 2011; 46: 659-667.
11. Uchida N, Wake A, Takagi S, Yamamoto H, Kato D, Matsuhashi Y et al. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant 2008; 14: 583-590. (Pubitemid 351494752)
12. Rocha V, Mohty M, Gluckman E, Rio B. Eurocord, reduced-intensity conditioning subcommittee of the Acute Leukaemia Working Party, et al. Reduced-intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies (review). Curr Opin Oncol 2009; 21(Suppl 1): S31-S34.
13. Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351: 2276-2285. (Pubitemid 39552743)
14. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005; 11: 945-956. (Pubitemid 41754712)
15. Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem H-P et al. Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. Blood 2009; 114: 702-708.
16. Arora M, Nagaraj S, Witte J, Defor TE, MacMillan M, Burns LJ et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009; 43: 149-153.
17. Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C et al. Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. Br J Haematol 2005; 130: 409-417. (Pubitemid 43899590)
18. Jagasia M, Giglia J, Chinratanalab W, Dixon S, Chen H, Frangoul H et al. Incidence and outcome of chronic graft-versus-host disease using National Institutes of Health consensus criteria. Biol Blood Marrow Transplant 2007; 13: 1207-1215. (Pubitemid 47413020)
19. Flowers MED, Parker PM, Johnston LJ, Matos AVB, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415-419. (Pubitemid 34761101)
20. Stewart BL, Storer B, Storek J, Deeg HJ, Storb R, Hansen JA et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004; 104: 3501-3506. (Pubitemid 39564419)
21. Leisenring WM, Martin PJ, Petersdorf EW, Regan AE, Aboulhosn N, Stern JM et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006; 108: 749-755. (Pubitemid 44061380)
22. Martin PJ, McDonald GB, Sanders JE, Anasetti C, Appelbaum FR, Deeg HJ et al. Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2004; 10: 320-327. (Pubitemid 38519570)
23. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
24. Sullivan KM. Graft-versus-host disease. In: Forman SJ, Blume KG, Thomas ED (eds). Bone Marrow Transplantation. Blackwell Scientific Publications: Boston, MA, USA 339-362, 1994.
25. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16: 232-237.
26. Alsultan A, Giller RH, Gao D, Bathurst J, Hild E, Gore L et al. GVHD after unrelated cord blood transplant in children: characteristics, severity, risk factors and influence on outcome. Bone Marrow Transplant 2011; 46: 668-675.
27. Mielcarek M, Martin PJ, Leisenring W, Flowers MED, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762. (Pubitemid 36842003)
28. Cho B-S, Min C-K, Eom K-S, Kim Y-J, Kim H-J, Lee S et al. Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia 2009; 23: 78-84.
29. Reen DJ. Activation and functional capacity of human neonatal CD4 T-cells (review). Vaccine 1998; 16: 1401-1408. (Pubitemid 28364675)
30. Kim YJ, Broxmeyer HE. Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance (review). Crit Rev Oncol Hematol 2011; 79: 112-126.
31. Risdon G, Gaddy J, Broxmeyer HE. Allogeneic responses of human umbilical cord blood. Blood Cells 1994; 20: 566-572.
32. Risdon G, Gaddy J, Stehman FB, Broxmeyer HE. Proliferative and cytotoxic responses of human cord blood T lymphocytes following allogeneic stimulation. Cell Immunol 1994; 154: 14-24. (Pubitemid 24084413)
33. Chen L, Cohen AC, Lewis DB. Impaired allogeneic activation and T-helper 1 differentiation of human cord blood naive CD4 T cells. Biol Blood Marrow Transplant 2006; 12: 160-171. (Pubitemid 43138011)
34. Nitsche A, Zhang M, Clauss T, Siegert W, Brune K, Pahl A. Cytokine profiles of cord and adult blood leukocytes: differences in expression are due to differences in expression and activation of transcription factors. BMC Immunology 2007; 8: 18.
35. Drohan L, Harding JJ, Holm B, Cordoba-Tongson E, Dekker CL, Holmes T et al. Selective developmental defects of cord blood antigen-presenting cell subsets. Hum Immunol 2004; 65: 1356-1369. (Pubitemid 39535299)